Interview with Philippe van der Hofstadt, Founder & CEO, B & C Group
Can you tell our readers about B&C Groups main mission and also highlight some of its most notable achievements and milestones since its founding in 1999? Earlier in my career,…
Address: Watson & Crick Hill, Rue Granbonpré 11, B-1348 Mont-Saint-Guibert,Belgium
Tel: +32 (0)10 237 444
Web: http://www.bnc-group.com/
B & C Group is a Packaging & Logistics Company solely dedicated to (Pre)Clinical Research.
Established in 1999 as a niche provider of ground transport for batched frozen specimen shipments, B & C was the first company of its kind to offer full specimen tracking and on-site data cleaning. Today we offer a unique combination of logistics services through our network.
B & C Group adds value to your clinical research logistics process by its unique approach on centralization and integration combined with experience, expertise and geographic reach.
Since January 2009, B & C Group has relocated its two sites in Mechelen and Wavre to the former Eli Lilly IMP Packaging & distribution facility in Mont-St-Guibert (South of Brussels – Belgium).
B & C provides integrated Packaging and Logistics services for the Clinical Trials sponsored or supported by:
Pharmaceutical Companies
Biotechnology Companies
Central Laboratories
Contract Research Organizations
Academic Institutions
Investigational Sites
Can you tell our readers about B&C Groups main mission and also highlight some of its most notable achievements and milestones since its founding in 1999? Earlier in my career,…
Speaking exclusively to PharmaBoardroom, Pedro Facon outlines the scope and aims of the new medicines roadmap that NIHDI has recently presented to the Belgian Ministry of Health following extensive stakeholder…
An Van Gerven took the reins of Pfizer’s BeLux affiliate just 9 months ago after a diverse range of roles at the company over the course of 12 years. She…
PDC*line Pharma’s Eric Halioula explains why he decided to establish a biotech in Belgium, outlines the progress that his immuno-oncology focused firm has made in clinical trials since our last…
Once primarily associated with dispensing medications alone, many pharmacies have now evolved into dynamic healthcare hubs, offering a diverse range of services that extend far beyond traditional prescription filling. Similarly,…
The concepts of patient-centricity and patient-centred healthcare systems have been much discussed in recent years but, in the opinion of Stefan Gijssels, there is still a long road to travel…
Pierre Boyer, GM at Servier BeLux for the past six years, outlines the unique characteristics and challenges of the Belgian market and shares the company’s 2030 strategy, its unique approach…
Gedeon Richter Benelux’s Isabelle de Walsche gives an update on the affiliate’s progress towards becoming a reference player in women’s health, looks back on some of her achievements over 11…
Luc Van Gorp is president of the Christian Mutuality, Belgium’s largest health insurance fund. In a wide-ranging recent conversation with PharmaBoardroom, Van Gorp expanded on some of the key themes…
Xavier De Cuyper of the Federal Agency for Medicines & Health Products (FAMHP), Belgium’s drug regulator, explains the FAMHP’s pandemic response and lessons learned, how the Agency is keeping on…
As part of the EU’s Pharmaceutical Strategy for Europe, the European Commission has come out with a set of proposals to revise EU pharmaceutical legislation. The reforms, which aim to…
Gábor Sztaniszláv talks through the global relevance of Belux to Amgen’s operations, some of the challenging market access conditions at play – especially for orphan drugs -, and how the…
Marc Gryseels of BACHI, Belgium’s over-the-counter (OTC) medicines association, highlights the organisation’s mission and vision, the key trends at play within the Belgian consumer healthcare market, and his industry’s significant…
See our Cookie Privacy Policy Here
